FDA clears IND application for natural killer cell-based COVID-19 therapy

The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer. CYNK-001 (Celularity) is an investigational, cryopreserved, allogeneic natural killer cell therapy derived from placental hematopoietic stem cells. “This investigational new drug application represents a significant step […]

Click here to view original web page at www.healio.com